Latest Daily Edition Stories

Sangamo’s Study Of Genome Editing In Rare Disease Is First To Target Effects On Humans

Biotech company Sangamo Therapeutics, headquartered in Richmond, Calif., is expected to release preliminary results next month in the first clinical trial using genome editing to treat real patients. In other health research news: a banking and regulatory adviser works to get private investors to bankroll a cure for blindness; the “perfect lab animal”? worms; and drug comparative effectiveness research.

First Generic Version Of EpiPen Injector Approved By FDA And Could Lower Cost Of Drug

Teva gets approval from the Food and Drug Administration to sell its version of the epinephrine auto-injector, but hasn’t yet revealed its pricing. Mylan, the manufacturer of the brand-name EpiPen, has faced public criticism and congressional investigations for raising the price of its lifesaving drug 450 percent since 2004.

If Doctors Use Your Data To Develop Treatments, Do They Need To Tell You?

Ethicists, patients, doctors and courts are wrestling with that question as efforts grow to expand care through better data and technology. Also, Stat offers a guide to CRISPR, and Madrigal Pharmaceuticals says one of its drugs has shown progress treating fatty liver disease.

Doctors Are Prescribing Fewer Opioids, Says AMA

The number of opioid prescriptions in the U.S. dropped 22 percent between 2013 and 2017, leading to an estimated 55 million fewer scripts, according to the doctors’ group. These numbers are part of the American Medical Association’s argument against proposed federal clinical practice legislation. Also in the news, an exposé on the marketing techniques used by some corners of big pharma regarding these medicines. Meanwhile, updates on California’s experiment in distributing fentanyl tests.

When CEO Pay Is Corrected, The Number Can Be Dramatic

In other health industry news, Allergan announced it will sell its women’s health, infectious-disease units, as well as a voluntary recall of nearly 170,000 birth control packs because of a packaging error that could lead to unintended pregnancy.